Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Heart Failure, Essential Hypertension
LCZ696 in Advanced LV Hypertrophy and HFpEF
Patients with advanced LVH and HFpEF will be randomly assigned in open-label fashion to receive LCZ696 titrated to 200 mg twice daily or valsartan titrated to 160 mg twice daily, and will be treated for 24 weeks.
- Trial name
- NCT03928158
- Testing
- LCZ 696, Valsartan
- Where
- Russia
- Volunteers
- 61 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure With Preserved Ejection Fraction
Provocative Tests for HFpEF
Diagnosing heart failure with preserved ejection fraction (HFpEF) in patients complaining exertional breathlessness can be challenging: diagnostic algorithms and scores have low sensitivity, and ageing-associated comorbidities…
- Trial name
- TEST-PEF (NCT06309550)
- Testing
- exercise test
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Istituto Auxologico Italiano
Heart Failure With Normal Ejection Fraction
Renal Hemodynamics in Patients With HFpEF
Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality.
- Trial name
- NCT03672591
- Testing
- Renal clearance examination
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Heart Failure, Obesity
Biomarkers in Patients With Suspected HFpEF
NT-proBNP does not adequately identify HF(pEF) in people with suspected HF at low levels, particularly in patients with obesity. This study will investigate: 1.
- Conditions
- Heart Failure, Obesity, Heart Failure With Preserved Ejection Fraction
- Trial name
- BIOPEF (NCT06101693)
- Testing
- Plasma biomarker levels
- Where
- 3 sites in United Kingdom
- Volunteers
- 1,028 people
- Sponsor
- NHS Greater Glasgow and Clyde
Heart Failure With Normal Ejection Fraction
Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF
Heart failure (HF) currently affects app. 2% of the western population and app. 10% of people >75 years. In about 50% of patients with symptomatic HF ejection fraction (EF) is preserved (HF-PEF).
- Trial name
- DECIPHER-HFpEF (NCT03251183)
- Testing
- Comprehensive Cardiovascular magnetic resonance (CMR), Blood sampling, TTE (EchoErgo)
- Where
- 7 sites in Germany
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Goethe University
Risk Reduction
Effect of Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With HF and HFpEF
The prevalence of type 2 diabetes mellitus (T2DM) in Qatar and nations worldwide has increased in recent decades into epidemic proportions. Cardiovascular (CVD) disease is the leading cause of death in T2DM patients.
- Trial name
- NCT03794518
- Testing
- Pioglitazone Plus dapaglifliozin
- Where
- Qatar
- Volunteers
- 648 people
- Sponsor
- Hamad Medical Corporation
Heart Failure, Heart Failure, Diastolic
MyoMobile Study: App-based Activity Coaching in Patients with Heart Failure and Preserved Ejection Fraction
The MyoMobile study is a single-center, randomized, controlled three-armed cohort study with prospective data collection to investigate the effect of a personalized mobile health intervention compared to usual care on the…
- Trial name
- MyoMobile (NCT04940312)
- Testing
- App-based physical activity coaching, No Intervention: Observational Cohort, Intervention Group 1
- Where
- Germany
- Volunteers
- 193 people
- Sponsor
- Johannes Gutenberg University Mainz
Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF
Clinical Feasibility of Cardiac Neuromodulation Therapy for Heart Failure With Preserved Ejection Fraction
This is an open-label pilot study to evaluate the feasibility of Cardiac Neuromodulation Therapy (CNT) in patients with high blood pressure and heart failure who require dual-chamber pacemaker implantation or replacement.
- Conditions
- Hypertension (HTN), Heart Failure With Preserved Ejection Fraction (HFpEF, Hypertension, Systolic
- Trial name
- NCT07598760
- Testing
- Moderato Plus device with Cardiac Neuromodulation Therapy
- Where
- 2 sites in Georgia
- Volunteers
- 20 people
- Sponsor
- BackBeat Medical Inc
Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic
Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure
Determine the impact of restoring normal heart rate response during exercise and daily activity in patients with heart failure and a preserved ejection fraction (HFpEF) and chronotropic incompetence (CI).
- Conditions
- Heart Failure With a Preserved Ejection Fraction, Heart Failure, Diastolic, Chronotropic Incompetence
- Trial name
- RAPID-HF (NCT02145351)
- Testing
- Rate adaptive atrial pacing using a dual-chamber pacemaker, Pacemaker system will be implanted but set to Pacing Off.
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mayo Clinic
HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
Tailored Exercise Training Study Among Adults With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is associated with a high morbidity and mortality burden. There are limited pharmacological options available for the treatment of HFpEF.
- Trial name
- TEXPEF (NCT07223242)
- Testing
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Texas Southwestern Medical Center
Heart Failure, Heart Failure Preserved Ejection Fraction
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
The purpose of this study is to evaluate the safety and effectiveness of tovinontrine compared to placebo to lower NT-proBNP in patients with chronic heart failure with preserved ejection fraction
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Trial name
- Cycle-2-PEF (NCT06215586)
- Testing
- Tovinontrine (CRD-750)
- Where
- 84 sites in United States, Australia and 13 more
- Volunteers
- 303 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Atrial Fibrillation, Heart Failure With Normal Ejection Fraction
Ablation Versus Medical Management of Atrial Fibrillation in HFpEF
This is a prospective non-blinded randomized control pilot study comparing the effect of pulmonary vein isolation against medical management of atrial fibrillation in patients with Heart Failure with preserved Ejection Fraction…
- Trial name
- AMPERE (NCT04282850)
- Testing
- Pulmonary Vein Isolation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Inova Health Care Services
HFpEF - Heart Failure With Preserved Ejection Fraction
Exercise Magnetic Resonance Imaging in Patients With Obesity Associated Heart Failure
To aim of the EXPOSURE study is to investigate the effects of epicardial fat on cardiac function, pericardial constraint and pulmonary artery vasodilatation using cardiac magnetic resonance (CMR) imaging at rest and during…
- Trial name
- EXPOSURE (NCT06514820)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- University Medical Center Groningen
Pulmonary Hypertension, Heart Failure
Metformin for Pulmonary Hypertension HFpEF
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
- Trial name
- PH-HFpEF (NCT03629340)
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of California, San Francisco
Heart Failure, Congestive
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
Heart failure with preserved ejection fraction or HFpEF, represents nearly 50% of all heart failure cases and is particularly common in the elderly. The disease has no current treatment options.
- Trial name
- NCT02772068
- Testing
- Istaroxime, Exercise
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Benjamin Levine
Hypertension, Pulmonary
A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
- Trial name
- CADENCE (NCT04945460)
- Testing
- Sotatercept 0.3 mg/kg, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
- Where
- 119 sites in United States, Belgium and 10 more
- Volunteers
- 165 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Chronic Heart Failure
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
This is a multi-center, randomized, double-blind, placebo-controlled study in subjects with stable heart failure with preserved ejection fraction (HFpEF) to evaluate the effects of 4 weeks treatment with subcutaneous MTP-131…
- Trial name
- NCT02814097
- Testing
- elamipretide
- Where
- 9 sites in Germany, Serbia
- Volunteers
- 46 people
- Sponsor
- Stealth BioTherapeutics Inc.
Obesity (BMI>30), Heart Failure With Preserved Ejection Fraction (HFPEF)
Pilot Study of Endoscopic Sleeve Gastroplasty for Obese Patients With Heart Failure and Preserved Ejection Fraction
This is a small research study to see whether losing weight with a minimally invasive weight-loss procedure called endoscopic sleeve gastroplasty (ESG) can help improve symptoms of a type of heart failure called HFpEF in adults…
- Trial name
- NCT07798219
- Testing
- Endoscopic sleeve gastroplasty (ESG)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure with Preserved Ejection Fraction
"HerzCheck" - Detection of Early Heart Failure Using Telemedicine in Structurally Weak Regions
This study is intended to provide a basis for decision-making for the improved medical care of patients with asymptomatic heart failure, especially in structurally weak regions.
- Trial name
- NCT05122793
- Testing
- Prevention offer
- Where
- Germany
- Volunteers
- 4,509 people
- Sponsor
- German Heart Institute
Heart Failure With Preserved Ejection Fraction, Chronotropic Incompetence
Effects of a Supervised Training Program on Functional Capacity in Patients With HFpEF and Chronotropic Incompetence
This is a prospective study, blinded for the evaluator, randomized (1:1:1:1) to receive standard management alone or combined with a program of training (aerobic alone or combined with strength exercises) that will be carried out…
- Trial name
- Training-HR (NCT05649787)
- Testing
- Supervised aerobic training, Supervised aerobic plus low to moderate-intensity strength training, Supervised aerobic plus moderate to high-intensity strength training
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia